FHA
CRSP icon

First Horizon Advisors’s CRISPR Therapeutics CRSP Stock Holding History

First Horizon Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$70.9K Sell
1,457
-621
-30% -$24K ﹤0.01% 831
2025
Q1 		$70.7K Buy
2,078
+39
+2% +$1.65K ﹤0.01% 794
2024
Q4 		$80.3K Buy
2,039
+511
+33% +$24.1K ﹤0.01% 759
2024
Q3 		$71.8K Sell
1,528
-44
-3% -$2.23K ﹤0.01% 841
2024
Q2 		$84.9K Buy
1,572
+136
+9% +$7.87K ﹤0.01% 726
2024
Q1 		$97.9K Buy
1,436
+8
+0.6% +$573 ﹤0.01% 699
2023
Q4 		$89.4K Sell
1,428
-127
-8% -$7.02K ﹤0.01% 702
2023
Q3 		$70.6K Sell
1,555
-542
-26% -$28K ﹤0.01% 725
2023
Q2 		$118K Sell
2,097
-574
-21% -$32.6K ﹤0.01% 600
2023
Q1 		$121K Buy
2,671
+513
+24% +$24.9K ﹤0.01% 594
2022
Q4 		$87.7K Sell
2,158
-287
-12% -$15.2K ﹤0.01% 659
2022
Q3 		$159K Sell
2,445
-543
-18% -$39.4K 0.01% 493
2022
Q2 		$181K Buy
+2,988
New +$176K 0.01% 483
2022
Q1 		– Sell
-986
Closed -$74K – 1817
2021
Q4 		$74K Buy
986
+190
+24% +$16.6K ﹤0.01% 782
2021
Q3 		$89K Buy
796
+215
+37% +$27K ﹤0.01% 709
2021
Q2 		$93K Buy
581
+159
+38% +$19.3K 0.01% 563
2021
Q1 		$51K Buy
+422
New +$63.7K ﹤0.01% 733

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Horizon Advisors's CRSP Position: Q2 2025 in Review

First Horizon Advisors reduced its CRISPR Therapeutics (CRSP) stake by 30% in Q2 2025, selling an estimated $24K and leaving 1,457 shares worth $70.9K. The position accounts for ﹤0.01% of the portfolio, ranked #831.

First Horizon Advisors first reported a position in CRSP in Q1 2021 and has held it in 17 quarters since. The position peaked at $181K in Q2 2022. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • First Horizon Advisors held 1,457 shares of CRISPR Therapeutics worth $70.9K as of Q2 2025.
  • First Horizon Advisors sold 621 CRISPR Therapeutics shares in Q2 2025, an estimated $24K.
  • CRISPR Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #831 holding.
  • First Horizon Advisors first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • First Horizon Advisors's CRISPR Therapeutics position peaked at $181K in Q2 2022.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.